These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Aug 16, 2018
SAN DIEGO, August 16, 2018 —Pfenex Inc. (NYSE American: PFNX) announced today that Dr. Hubert Chen has resigned from his role as Chief Medical and Scientific Officer, effective September 2,...
-
Aug 8, 2018
SAN DIEGO, August 8, 2018 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Jul 25, 2018
SAN DIEGO, California – July 25, 2018 -- Pfenex Inc. (NYSE AMERICAN: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression...
-
Jul 12, 2018
SAN DIEGO July 12, 2018 -- Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of...
-
Jun 22, 2018
SAN DIEGO, June 22, 2018 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve...
-
Jun 14, 2018
SAN DIEGO, June 14, 2018 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the JMP Securities 2018 Life Science Conference in New York City. President and Chief...
-
Jun 11, 2018
SAN DIEGO, June 11, 2018 -- Pfenex (NYSE American: PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenex’s lead drug candidate,...
-
May 30, 2018
SAN DIEGO, May 30, 2018 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the Jefferies 2018 Global Healthcare Conference in New York City. President and Chief...
-
May 29, 2018
SAN DIEGO, May 25, 2018 — Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve...
-
May 23, 2018
SAN DIEGO, May 23, 2018 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve...